Jyong Biotech (NASDAQ:MENS) Shares Gap Up – Time to Buy?

Jyong Biotech Ltd. (NASDAQ:MENS) shares gapped up prior to trading on Wednesday . The stock had previously closed at $30.36, but opened at $33.00. Jyong Biotech shares last traded at $32.80, with a volume of 36,671 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Jyong Biotech Stock Up 8.5%

The business has a fifty day moving average price of $48.09.

Hedge Funds Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets bought a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,698 shares of the company’s stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.